Glioma stem cell research for the development of immunotherapy.

Neurosurgery Clinics of North America
Jianfei JiJohn S Yu

Abstract

Glioma, especially high-grade glioblastoma multiforme (GBM), is the most common and aggressive type of brain tumor, accounting for about half of all the primary brain tumors. Despite continued advances in surgery, chemotherapy, and radiotherapy, the clinical outcomes remain dismal. The 2-year survival rate of GBM is less than 30%. Better understanding of GBM biology is needed to develop novel therapies. Recent studies have demonstrated the existence of a small subpopulation of cells with stemlike features called cancer stem cells (CSCs). These GBM CSCs are self renewable and highly tumorigenic. They not only are chemo-radio resistant but also often contain multidrug resistance genes and drug transporter genes. These characteristics enable GBM CSCs to survive standard cytotoxic therapies. Among GBM CSCs, CD133(+) cells are a well-defined population and are prospectively isolated by their cell-surface marker. Increasing data show that the presence of CD133(+) CSCs highly correlates with patient survival, making these cells an ideal immunotherapy target population. The authors have reviewed recent studies related with GBM CSCs (particularly CD133(+) CSCs) and the novel therapeutic strategies targeting these cells.

References

May 1, 1995·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·D L ShawlerH Fakhrai
Jul 1, 1998·Journal of Neurosurgery·G E PlautzS Shu
Oct 1, 1998·International Journal of Cancer. Journal International Du Cancer·H OkadaM E Bozik
Dec 10, 1999·Human Molecular Genetics·M A MawM J Denton
Mar 7, 2000·Frontiers in Bioscience : a Journal and Virtual Library·J S Smith, R B Jenkins
Dec 20, 2000·Proceedings of the National Academy of Sciences of the United States of America·N UchidaI L Weissman
Nov 2, 2001·Nature·T ReyaI L Weissman
Jul 12, 2002·Current Gene Therapy·N G Rainov, C M Kramm
Jul 23, 2002·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Andy J G PötgensHans-Georg Frank
Nov 27, 2002·Proceedings of the National Academy of Sciences of the United States of America·Monica L GuzmanCraig T Jordan
Mar 12, 2003·Proceedings of the National Academy of Sciences of the United States of America·Muhammad Al-HajjMichael F Clarke
Dec 3, 2003·Proceedings of the National Academy of Sciences of the United States of America·Houman D HemmatiHarley I Kornblum
Jan 9, 2004·Proceedings of the National Academy of Sciences of the United States of America·Toru KondoTetsuya Taga
Jun 23, 2004·Critical Reviews in Oncology/hematology·Stewart Sell
Jul 10, 2004·Blood·Charlotte V CoxAllison Blair
Oct 7, 2004·Cancer Research·Hiroko OhgakiPaul Kleihues
Nov 19, 2004·Nature·Sheila K SinghPeter B Dirks
Nov 24, 2004·Oncogene·Xiangpeng YuanJohn S Yu
Feb 8, 2005·The International Journal of Biochemistry & Cell Biology·Sergey V ShmelkovShahin Rafii
Apr 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Florence LefrancRobert Kiss
Apr 2, 2005·Nature Reviews. Cancer·Brian J P Huntly, D Gary Gilliland
Aug 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Linda M LiauMichael D Roth
Oct 18, 2005·Cancer Cell·Michael D TaylorRichard J Gilbertson
Dec 3, 2005·Cancer Research·Anne T CollinsNorman J Maitland
Feb 4, 2006·Cell Death and Differentiation·A EramoR De Maria
Mar 25, 2006·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Stewart Sell
Sep 26, 2006·Nature Medicine·Daniela S KrauseRichard A Van Etten
Sep 26, 2006·Nature Medicine·Liqing JinJohn E Dick

❮ Previous
Next ❯

Citations

Mar 13, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christine E BrownMichael C Jensen
Aug 1, 2014·Expert Opinion on Therapeutic Targets·Ichiro Nakano
Dec 28, 2011·Expert Opinion on Biological Therapy·Zhenhua LiJohn S Yu
Jan 24, 2016·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Cíntia J KiekowGrace Gosmann
Jul 4, 2012·Neurosurgery Clinics of North America·Winward ChoyIsaac Yang
Aug 17, 2010·Mitochondrion·Michael V BerridgeAn S Tan
Apr 3, 2012·Biochemical and Biophysical Research Communications·Yao QiXiu-Bao Ren
Mar 20, 2015·Molecular Biology of the Cell·Wei ZhaoYi-Xue Xue
Apr 19, 2013·Cell Transplantation·Der-Yang ChoLi-Hui Ho
Sep 12, 2017·The Cochrane Database of Systematic Reviews·Elie A AklHolger Schünemann
Apr 12, 2017·American Journal of Clinical Pathology·Helene GeddertEvgeny A Moskalev
Aug 29, 2014·Journal of Neuro-oncology·Eli T SayeghAndrew T Parsa
Aug 31, 2012·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Jian-Qiang LuVivek Mehta
May 24, 2017·Molecular Medicine Reports·Xianfeng GaoJingwei Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.